Anti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|19|2680-2701

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.19, 2012-06, pp. : 2680-2701

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

By Troiani Teresa   Martinelli Erika   Orditura Michele   De Vita Ferdinando   Ciardiello Fortunato   Morgillo Floriana  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 949-959

Informa Healthcare

Access to resources Recommend Favorite

Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology

By  

Current Drug Metabolism, Vol. 18, Iss. 3, 2017-03 ,pp. : 186-198

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas   Cherrington Julie M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer

By Zámečníkova Adriana  

Expert Opinion on Drug Discovery, Vol. 9, Iss. 1, 2014-01 ,pp. : 77-92

Informa Healthcare

Access to resources Recommend Favorite

A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 14, 2007-07 ,pp. : 1408-1422

Bentham Science Publishers

Access to resources Recommend Favorite